16
booklets in the field of providing educational information to healthcare providers and female patients of childbearing potential of the risks associated with the use of mycophenolate-containing products during pregnancy and the appropriate steps to manage these risks
44
providing educational information to healthcare providers and female patients of childbearing potential of the risks associated with the use of mycophenolate-containing products during pregnancy and the appropriate steps to manage these risks via an Internet website; maintaining a pregnancy registry for the purpose of documenting maternal and fetal outcomes in order to further characterize the risk of mycophenolate mofetil (MMF) / mycophenolic acid (MPA) fetal exposure
45
administering a regulatory compliance program in the field of prescription medicine to prevent unplanned pregnancy and to provide pregnancy planning, thereby seeking to minimize and limit fetal exposure by informing healthcare providers and female patients of the risks associated with the use of mycophenolate-containing products during pregnancy and the appropriate steps to manage these risks